Kobe Yuen

7.7k total citations · 1 hit paper
27 papers, 623 citations indexed

About

Kobe Yuen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Kobe Yuen has authored 27 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 7 papers in Surgery. Recurrent topics in Kobe Yuen's work include Cancer Immunotherapy and Biomarkers (15 papers), Prostate Cancer Treatment and Research (12 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Kobe Yuen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Prostate Cancer Treatment and Research (12 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Kobe Yuen collaborates with scholars based in United States, United Kingdom and France. Kobe Yuen's co-authors include Jennifer L. Gerton, Sanjeev Mariathasan, Brian D. Slaughter, Edward E. Kadel, Christopher J. Sweeney, Patrick Williams, Thomas Powles, Jennifer Doss, Charles G. Drake and Gary L. Buchschacher and has published in prestigious journals such as Cell, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Kobe Yuen

25 papers receiving 613 citations

Hit Papers

Atezolizumab with enzalutamide versus enzalutamide alone ... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    2022 157 citations Thomas Powles, Kobe Yuen et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kobe Yuen United States 13 300 253 249 193 87 27 623
Emily F. Gaudiano United States 7 294 1.0× 151 0.6× 545 2.2× 176 0.9× 213 2.4× 9 776
Sandy Larson United States 8 170 0.6× 94 0.4× 133 0.5× 148 0.8× 92 1.1× 12 402
Eric D. Routh United States 8 191 0.6× 81 0.3× 497 2.0× 112 0.6× 85 1.0× 15 699
John Bothos United States 10 179 0.6× 94 0.4× 334 1.3× 43 0.2× 35 0.4× 19 542
Bingsheng Sun China 13 128 0.4× 119 0.5× 217 0.9× 51 0.3× 136 1.6× 24 481
Rita Mitnacht‐Kraus Germany 8 95 0.3× 132 0.5× 260 1.0× 83 0.4× 56 0.6× 14 458
Sara Chiblak Germany 8 190 0.6× 109 0.4× 141 0.6× 50 0.3× 78 0.9× 12 394
Preston D. Moore United States 5 193 0.6× 144 0.6× 121 0.5× 87 0.5× 67 0.8× 9 381
Charles P. Xavier United States 8 71 0.2× 69 0.3× 292 1.2× 59 0.3× 55 0.6× 12 396
Ilsa Coleman United States 5 116 0.4× 114 0.5× 203 0.8× 99 0.5× 70 0.8× 7 433

Countries citing papers authored by Kobe Yuen

Since Specialization
Citations

This map shows the geographic impact of Kobe Yuen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kobe Yuen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kobe Yuen more than expected).

Fields of papers citing papers by Kobe Yuen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kobe Yuen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kobe Yuen. The network helps show where Kobe Yuen may publish in the future.

Co-authorship network of co-authors of Kobe Yuen

This figure shows the co-authorship network connecting the top 25 collaborators of Kobe Yuen. A scholar is included among the top collaborators of Kobe Yuen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kobe Yuen. Kobe Yuen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chou, William, Kobe Yuen, Ann Lazar, et al.. (2025). Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 13(3). e010528–e010528. 5 indexed citations
2.
Sweeney, Christopher J., Chang Xu, Jie He, et al.. (2024). Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 30(18). 4115–4122. 7 indexed citations
3.
4.
Sweeney, Christopher, Ryon P. Graf, David Fabrizio, et al.. (2023). Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.. Journal of Clinical Oncology. 41(6_suppl). LBA249–LBA249. 1 indexed citations
5.
Lyalina, Svetlana, Guadalupe Ortiz-Muñoz, Kobe Yuen, et al.. (2023). Abstract 4439: Negative impact of the GABA pathway on aPD(L)1 immunotherapy. Cancer Research. 83(7_Supplement). 4439–4439. 1 indexed citations
6.
Fehlings, Michael, Leesun Kim, Xiangnan Guan, et al.. (2022). Single-cell analysis reveals clonally expanded tumor-associated CD57 + CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade. Journal for ImmunoTherapy of Cancer. 10(8). e004759–e004759. 26 indexed citations
7.
Husain, Bushra, et al.. (2022). Cell-based receptor discovery identifies host factors specifically targeted by the SARS CoV-2 spike. Communications Biology. 5(1). 788–788. 3 indexed citations
8.
Powles, Thomas, Kobe Yuen, Silke Gillessen, et al.. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine. 28(1). 144–153. 157 indexed citations breakdown →
9.
Petrylak, Daniel P., Yohann Loriot, David R. Shaffer, et al.. (2021). Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research. 27(12). 3360–3369. 54 indexed citations
10.
Fong, Lawrence, Michael J. Morris, Oliver Sartor, et al.. (2021). A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(17). 4746–4756. 33 indexed citations
11.
Wagle, Marie-Claire, Joseph Castillo, Shrividhya Srinivasan, et al.. (2020). Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunology Research. 8(7). 844–850. 6 indexed citations
12.
Verschueren, Erik, Bushra Husain, Kobe Yuen, et al.. (2020). The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome. Cell. 182(2). 329–344.e19. 66 indexed citations
13.
14.
Sweeney, Christopher J., Silke Gillessen, Dana E. Rathkopf, et al.. (2020). Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 80(16_Supplement). CT014–CT014. 47 indexed citations
15.
Yuen, Kobe, Congfen Li, Deepali Rishipathak, et al.. (2019). Abstract 2676: Associations of peripheral biomarkers to outcomes to anti-PD-L1 immune checkpoint blockade in metastatic urothelial cancer. 2676–2676. 1 indexed citations
16.
Yuen, Kobe & Jennifer L. Gerton. (2018). Taking cohesin and condensin in context. PLoS Genetics. 14(1). e1007118–e1007118. 31 indexed citations
17.
Mariathasan, Sanjeev, Shannon J. Turley, Dorothee Nickles, et al.. (2017). TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma. Annals of Oncology. 28. xi30–xi30. 8 indexed citations
18.
Aoto, Kazushi, Linda J. Sandell, Naomi E. Butler Tjaden, et al.. (2015). Mef2c-F10N enhancer driven β-galactosidase (LacZ) and Cre recombinase mice facilitate analyses of gene function and lineage fate in neural crest cells. Developmental Biology. 402(1). 3–16. 27 indexed citations
19.
Yuen, Kobe, Baoshan Xu, Ian D. Krantz, & Jennifer L. Gerton. (2015). NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR. Cell Reports. 14(1). 93–102. 24 indexed citations
20.
Yuen, Kobe, et al.. (2015). Etiology and pathogenesis of the cohesinopathies. Wiley Interdisciplinary Reviews Developmental Biology. 4(5). 489–504. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emily F. Gaudiano Breakdown of academic impact, for papers by Sandy Larson Breakdown of academic impact, for papers by Eric D. Routh Breakdown of academic impact, for papers by John Bothos Breakdown of academic impact, for papers by Bingsheng Sun Breakdown of academic impact, for papers by Rita Mitnacht‐Kraus Breakdown of academic impact, for papers by Sara Chiblak Breakdown of academic impact, for papers by Preston D. Moore Breakdown of academic impact, for papers by Charles P. Xavier Breakdown of academic impact, for papers by Ilsa Coleman
Rankless by CCL
2026